EBG MedAustron GmbH

EBG MedAustron GmbH specializes in advanced ion therapy systems for cancer treatment. Specifically, they develop and operate devices like MATEO and MAPTA, which deliver high-precision proton and carbon ion radiotherapy. These technologies are designed to target tumors with localized precision while minimizing exposure to surrounding healthy tissue, making them suitable for complex or localized cancer cases.

EBG MedAustron GmbH is headquartered in Austria. Their ion therapy systems, including MATEO and MAPTA, are authorized for clinical use in the European Union under applicable medical device regulations. The company’s devices are registered in the EU’s eudamed database, which tracks authorized medical devices within the region.

EBG MedAustron GmbH’s devices, such as MATEO and MAPTA, fall under EU Class IIb classification. This classification is assigned based on the risk associated with the device—Class IIb devices are considered higher-risk than Class I or IIa but not as high as Class III. The classification influences regulatory requirements, including clinical evaluation and conformity assessment procedures.

Yes, EBG MedAustron GmbH’s devices are registered in the eudamed database, which is the official EU registry for medical devices. This database is maintained by the European Commission and serves as a transparent resource for stakeholders—including healthcare professionals, regulators, and patients—to verify the authorization status of devices marketed in the EU.